Advertisement
JOGC

Guideline No. 422e: Menopause and Cardiovascular Disease

Published:November 16, 2021DOI:https://doi.org/10.1016/j.jogc.2021.09.010

      ABSTRACT

      Objective

      Provide strategies for improving the care of perimenopausal and postmenopausal women based on the most recent published evidence.

      Target Population

      Perimenopausal and postmenopausal women.

      Benefits, Harms, and Costs

      Target population will benefit from the most recent published scientific evidence provided via the information from their health care provider. No harms or costs are involved with this information since women will have the opportunity to choose among the different therapeutic options for the management of the symptoms and morbidities associated with menopause, including the option to choose no treatment.

      Evidence

      Databases consulted were PubMed, MEDLINE, and the Cochrane Library for the years 2002–2020, and MeSH search terms were specific for each topic developed through the 7 chapters.

      Validation Methods

      The authors rated the quality of evidence and strength of recommendations using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. See online Appendix A (Tables A1 for definitions and A2 for interpretations of strong and weak recommendations).

      Intended Audience

      physicians, including gynaecologists, obstetricians, family physicians, internists, emergency medicine specialists; nurses, including registered nurses and nurse practitioners; pharmacists; medical trainees, including medical students, residents, fellows; and other providers of health care for the target population.

      SUMMARY STATEMENTS

      • 1
        Women who initiate menopausal hormone therapy shortly after menopause are, in general, at low risk for events in the next few years (high). Evidence supports aggressive identification and modification of risk factors as the most effective means of reducing cardiovascular risk (high).
      • 2
        Women who initiate menopausal hormone therapy 10 or more years after menopause are at increased risk for adverse cardiac events (high).
      • 3
        With respect to stroke, increased risk has been identified in all age groups using standard formulations of menopausal hormone therapy; however, the incidence in young women is extremely low (low).
      • 4
        Incidence of venous thrombotic events increase with age (> 60 y) and BMI, even in otherwise healthy women; menopausal hormone therapy increases the risk (high).
      • 5
        Menopausal hormone therapy is not indicated for primary or secondary prevention of cardiovascular disease (moderate).
      • 6
        Women with premature or early-onset menopause appear to be at an increased risk of adverse cardiovascular outcomes, and this risk may be prevented by the use of menopausal hormone therapy until the average age of menopause (moderate).
      • 7
        Menopausal hormone therapy increases the risk of venous thromboembolism; oral and combined hormone therapy preparations are more closely associated with risk of venous thromboembolism than either with transdermal preparations or estrogen alone (moderate).
      • 8
        There is a lack of high-quality data to provide guidance on the impact of routes of estrogen administration on the risk of venous thrombotic events or cardiovascular disease (low).

      RECOMMENDATIONS

      • 1
        Menopausal hormone therapy should be offered as the most effective treatment for the relief of menopausal symptoms (strong, high).
      • 2
        When prescribing menopausal hormone therapy, the lowest effective dose of estrogen, and, where indicated, estrogen-only therapy, should be offered to minimize the associated risk of venous thromboembolism (conditional, low).
      • 3
        The lowest effective dose of estrogen, either oral or transdermal, should be prescribed to minimize the risk of stroke (conditional, low).
      • 4
        When prescribing combined hormone therapy, choice of progestogen should favour those least likely to affect markers for cardiovascular disease. (strong, moderate).
      • 5
        A tissue selective estrogen complex may be used without a progestin to provide menopausal hormone therapy and uterine protection for relief of early menopausal symptoms (conditional, moderate). To date, these agents do not appear to be associated with cardiovascular risk.

      Keywords

      Abbreviations:

      CVD (cardiovascular disease), DOPS (Danish Osteoporosis Prevention Study), ELITE (Early Versus Late Intervention Trial With Estradiol), KEEPS (Kronos Early Estrogen Prevention Study), MHT (menopausal hormone therapy), SERM (selective estrogen receptor modulator), SMART (Selective estrogens, Menopause and Response to Therapy), VTE (venous thromboembolism), WHI (Women's Health Initiative)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Obstetrics and Gynaecology Canada
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      REFERENCES

        • Boardman HM
        • Hartley L
        • Eisinga A
        • et al.
        Hormone therapy for preventing cardiovascular disease in post-menopausal women.
        Cochrane Database Syst Rev. 2015; CD002229
        • Manson JE
        • Bassuk SS
        • Merz CNB
        • et al.
        Menopausal hormone therapy and national time trends in mortality: Cautions regarding causal inference.
        Menopause. 2017; 24: 874-876
        • Harman SM
        • Black DM
        • Naftolin F
        • et al.
        Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: A randomized trial.
        Ann Intern Med. 2014; 161: 249-260
        • Hodis HN
        • Mack WJ
        • Henderson VW
        • et al.
        Vascular effects of early versus late postmenopausal treatment with estradiol.
        N Engl J Med. 2016; 374: 1221-1231
        • Hodis HN
        • Mack WJ
        • Shoupe D
        • et al.
        Methods and baseline cardiovascular data from the early versus late intervention trial with estradiol testing the menopausal hormone timing hypothesis.
        Menopause. 2015; 22: 391-401
        • Miller VM
        • Hodis HN
        • Lahr BD
        • et al.
        Changes in carotid artery intima-media thickness 3 years after cessation of menopausal hormone therapy: Follow-up from the kronos early estrogen prevention study.
        Menopause. 2019; 26: 24-31
        • Grossman DC
        • Curry SJ
        • et al.
        • U. S. Preventive Services Task Force
        Hormone therapy for the primary prevention of chronic conditions in postmenopausal women: Us preventive services task force recommendation statement.
        JAMA. 2017; 318: 2224-2233
        • Muka T
        • Oliver-Williams C
        • Kunutsor S
        • et al.
        Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: A systematic review and meta-analysis.
        JAMA Cardiol. 2016; 1: 767-776
        • Kalantaridou SN
        • Naka KK
        • Papanikolaou E
        • et al.
        Impaired endothelial function in young women with premature ovarian failure: Normalization with hormone therapy.
        J Clin Endocrinol Metab. 2004; 89: 3907-3913
        • Lokkegaard E
        • Jovanovic Z
        • Heitmann BL
        • et al.
        The association between early menopause and risk of ischaemic heart disease: Influence of hormone therapy.
        Maturitas. 2006; 53: 226-233
        • The Nams Hormone Therapy Position Statement Advisory Panel
        The 2017 hormone therapy position statement of the north american menopause society.
        Menopause. 2017; 24: 728-753
        • Srivaratharajah K
        • Abramson BL
        Identifying and managing younger women at high risk of cardiovascular disease.
        CMAJ. 2019; 191: E159-EE63
        • Komm BS
        • Thompson JR
        • Mirkin S
        Cardiovascular safety of conjugated estrogens plus bazedoxifene: Meta-analysis of the smart trials.
        Climacteric. 2015; 18: 503-511
        • Schierbeck LL
        • Rejnmark L
        • Tofteng CL
        • et al.
        Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: Randomised trial.
        BMJ. 2012; 345: e6409
        • Vinogradova Y
        • Coupland C
        • Hippisley-Cox J
        Use of hormone replacement therapy and risk of venous thromboembolism: Nested case-control studies using the qresearch and cprd databases.
        BMJ. 2019; 364: k4810
        • Stuenkel CA
        • Davis SR
        • Gompel A
        • et al.
        Treatment of symptoms of the menopause: An endocrine society clinical practice guideline.
        J Clin Endocrinol Metab. 2015; 100: 3975-4011
        • Formoso G
        • Perrone E
        • Maltoni S
        • et al.
        Short-term and long-term effects of tibolone in postmenopausal women.
        Cochrane Database Syst Rev. 2016; 10CD008536
        • Yusuf S
        • Bosch J
        • Dagenais G
        • et al.
        Cholesterol lowering in intermediate-risk persons without cardiovascular disease.
        N Engl J Med. 2016; 374: 2021-2031
        • McNeil JJ
        • Wolfe R
        • Woods RL
        • et al.
        Effect of aspirin on cardiovascular events and bleeding in the healthy elderly.
        N Engl J Med. 2018; 379: 1509-1518
        • Gaziano JM
        • Brotons C
        • Coppolecchia R
        • et al.
        Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (arrive): A randomised, double-blind, placebo-controlled trial.
        Lancet. 2018; 392: 1036-1046